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Heparan sulfate proteoglycans in glomerular inflammation.
Heparan sulfate proteoglycans (HSPGs) are glycoproteins
consisting of a core protein to which linear heparan sulfate
side chains are covalently attached. These heparan sulfate side
chains can be modified at different positions by several enzymes,
which include N-deacetylases, N- and O-sulfotransferases, and
an epimerase. These heparan sulfate modifications give rise to
an enormous structural diversity, which corresponds to the vari-
ety of biologic functions mediated by heparan sulfate, including
its role in inflammation. The HSPGs in the glomerular basement
membrane (GBM), perlecan, agrin, and collagen XVIII, play
an important role in the charge-selective permeability of the
glomerular filter. In addition to these HSPGs, various cell types
express HSPGs at their cell surface, which include syndecans,
glypicans, CD44, and betaglycan.
During inflammation, HSPGs, especially heparan sulfate, in
the extracellular matrix (ECM) and at the surface of endothelial
cells bind chemokines, which establishes a local concentration
gradient recruiting leukocytes. Endothelial and leukocyte cell
surface HSPGs also play a role in their direct adhesive interac-
tions via other cell surface adhesion molecules, such as selectins
and b2 integrin. Activated leukocytes and endothelial cells ex-
ert heparanase activity, resulting in degradation of heparan sul-
fate moieties in the ECM, which facilitates leukocyte passage
into tissues and the release of heparan sulfate–bound factors. In
various renal inflammatory diseases the expression of agrin and
GBM-associated heparan sulfate is decreased, while the expres-
sion of CD44 is increased. Heparan sulfate or heparin prepa-
rations affect inflammatory cell behavior and have promising
therapeutic, anti-inflammatory properties by preventing leuko-
cyte adhesion/influx and tissue damage.
Heparan sulfate proteoglycans (HSPGs) are a class
of biomolecules with structural and regulatory functions
that consist of a core protein with covalently attached
heparan sulfate sugar side chains. HSPGs are located
in basement membranes and at cell surfaces of various
cell types, and are involved in biologic processes such
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as glomerular filtration, cell adhesion, migration, prolif-
eration, and differentiation [1–4], which are mediated
by binding of chemokines, cytokines, enzymes, growth
factors, or other bioactive molecules [5]. The common
denominator of all HSPGs is the heparan sulfate side
chain, which belongs to the family of strongly negatively
charged glycosaminoglycans (GAGs) [6, 7]. The hep-
aran sulfate side chain consists of up to 300 alternating
N-acetyl-glucosamine a1 → 4 glucuronate b1 → 4
residues, which both can be modified extensively. Modifi-
cation of heparan sulfate starts with the N-deacetylation
and N-sulfation of N-acetyl-glucosamine by different iso-
forms of glucosaminyl N-deacetylase/N-sulfotransferases
(NDSTs). The subsequent steps are C-5 epimerization of
glucuronate to iduronate by the enzyme D-glucuronyl
C5-epimerase and O-sulfation at various positions (C-2,
C-3, and C-6) by different sulfotransferases (Fig. 1). Due
to the sequential order of the modification reactions and
the different enzymes involved, the initial distribution
of N-sulfate groups will greatly determine the location
of iduronate residues and O-sulfate groups within the
heparan sulfate side chains. This results in a block-like
structure in which alternating N-acetylated, mixed N-
acetylated/N-sulfated and N-sulfated (heparin-like) do-
mains are found [6–8]. Since a heparan sulfate chain can
contain up to 150 disaccharide units, the modification
process gives rise to an enormous potential of different
heparan sulfate domains [4–6]. Such specific heparan sul-
fate domains are involved in the binding and modula-
tion of specific proteins (Table 1) [1, 5, 8–12]. The spe-
cific binding of ligands to heparan sulfate depends on
the degree of modification and is most likely determined
by the spatial presentation of specific carboxyl and sul-
fate groups [5, 12]. The functional consequences of lig-
and binding to HSPGs are (1) immobilization of the lig-
and and increase of its local concentration; (2) induc-
tion of conformational changes, both within the hep-
aran sulfate chain and/or its ligand, allowing presentation
to a signaling receptor; (3) induction of oligomerization
of bound growth factors or chemokines leading to re-
ceptor dimerization and signaling; and (4) protection
of growth factors or chemokines from denaturation or
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Fig. 1. The modification reactions in the
biosynthesis of heparan sulfate. The first
modification step, N-deacetylation and
N-sulfation of N-acetyl-glucosamine, has an
important function because the remaining
N-acetylated regions will largely escape
subsequent modifications. The N-deacety-
lase/N-sulfotransferase (NDST) enzymes
(four isozymes) are responsible for this
modification. N-sulfated regions are
subject to the next modification steps,
which include C-5 epimerization of glu-
curonate to iduronate (by D-glucuronyl
C5-epimerase) and O-sulfation at various
positions. The various sulfotransferases
include 2-O-sulfotransferase (2-O-sulfation
of iduronate), three or more isozymes of 6-O-
sulfotransferase (6-O-sulfation of N-acetyl/-
sulfo-glucosamine), and six isozymes of
3-O-sulfotransferase (3-O-sulfation of
N-unsubstituted/sulfo-glucosamine). Abbre-
viations are: GlcA, glucuronate; GlcNAc,
N-acetyl-glucosamine; GlcNSO3, N-sulfo-
glucosamine; IdoA, iduronate; IdoA, 2S,
2-O sulfated iduronate; GlcNSO3, 6S, 6-O
sulfated N-sulfo-glucosamine; GlcNSO3, 3S,
3-O sulfated N-sulfo-glucosamine.
proteolysis [1, 5, 7–9, 13]. The best-characterized hep-
aran sulfate–ligand interaction, important for coagula-
tion and inflammation, is the binding of antithrombin III
to heparan sulfate [5, 8, 12]. This high-affinity binding
is mediated through a specific pentasaccharide sequence
(N-acetylglucosamine 6-O sulfate → glucuronic acid →
glucosamine N-sulfate 3-O sulfate ± 6-O sulfate →
iduronic acid 2-O sulfate → glucosamine N-sulfate 6-O
sulfate). Within this sequence, the 3-O sulfate group is
essential for high-affinity antithrombin III binding and
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Table 1. Groups of heparan sulfate–binding proteins
HS-binding proteins
Chemokines Enzyme inhibitors
IL-8, RANTES, MIP-1,
MCP-1, SDF-1a, PF-4,
eotaxin, IP-10, fractalkine,
SLC, TARC
Serine protease inhibitors
Selectins Extracellular matrix proteins
L selectin (CD62L), P selectin
(CD62P)
Fibronectin, collagens,
vitronectin, laminin, fibrillin,
thrombospondin
Integrins Lipoproteins
Mac-1 (CD11b/CD18) Low and very low density
lipoproteins, apolipoproteins
Cell adhesion molecules Receptor proteins
NCAM, PECAM-1 (CD31) Steroid receptor, channel
protein, growth factor
receptors
Growth factors Protease inhibitors
Fibroblast growth factors,
hepatocyte growth factor,
epidermal growth factor,
vascular endothelial growth
factors, transforming growth
factor, platelet-derived
growth factor, insulin-like
growth factor
Antithrombin III, heparin
cofactor II, protease nexin I,
protein C inhibitor, mucus
proteinase inhibitor
Enzymes Viral coat proteins
Proteases, HBP/Cap37,
esterases, lipolytic enzymes,
phospatases, kinases,
carbohydrate hydrolases,
eliminases, transferases,
nucleases, polymerases,
topoisomerases, oxidases,
synthetases, dismutases
HSV, HIV, Dengue
Nuclear proteins
Transcription factors, histones
Abbreviations are: IL-8, interleukin-8; RANTES, regulated on activation, nor-
mal T-cell expressed and secreted; MIP-1, macrophage inflammatory protein-
1; MCP-1, monocyte chemoattractant protein-1; SDF-1a, stromal cell-derived
factor-1a; PF-4, platelet factor-4; IP-10, interferon-c-inducible protein-10; SLC,
secondary lymphoid-tissue chemokine; TARC, thymus and activation-regulated
chemokine; Mac-1, macrophage-1antigen; NCAM, neural cell adhesion molecule;
PECAM-1, platelet-endothelial cell adhesion molecule-1; HBP, heparin binding
protein; CAP37, cationic antimicrobial protein of 37 kD; HSV, herpes simplex
virus; HIV, human immunodeficiency virus [1, 5, 8–12].
enhancement of antithrombin III activity. However, a
mouse deficient in the enzyme 3-O-sulfotransferase that
catalyses the sulfation at the 3-O position does not show
changes in normal homeostasis [8, 14]. The antithrom-
bin III–cell surface heparan sulfate complex inhibits neu-
trophil rolling, adhesion, and migration in inflammatory
reactions, most likely by interfering with inflam-
matory signaling pathways. Other factors involved
in inflammation, especially chemokines, like platelet
factor-4 (PF-4), stromal cell-derived factor-1a (SDF-
1a), interleukin-8 (IL-8), growth-regulated oncogene-a
(GRO-a), RANTES (regulated on activation, normal
T-cell expressed and secreted), macrophage inflamma-
tory protein-1a (MIP-1a), monocyte chemoattractant
protein-1 (MCP-1), interferon-c–inducible protein-10
(IP-10), fractalkine, eotaxin, secondary lymphoid-tissue
chemokine (SLC), and thymus and activation-regulated
chemokine (TARC), but also selectins, integrins, heparin-
binding protein (HBP)/cationic antimicrobial protein of
37 kD (CAP37), and the heparan sulfate–degrading en-
zyme heparanase are able to bind heparan sulfate and/or
heparin. However, the specific sequences within hep-
aran sulfate and/or heparin, to which these inflammatory
factors bind to, are less well characterized than for an-
tithrombin III [10–12, 15–27].
Quantitative changes in HSPGs have been observed
in various glomerulonephritides, in a number of protein-
uric nephropathies, including diabetic nephropathy, and
in renal sclerosis/fibrosis [3, 28–32]. Mice lacking the hep-
aran sulfate–modifying enzyme 2-sulfotransferase do not
develop kidneys, which demonstrates that the regulated
synthesis of heparan sulfate can affect kidney morpho-
genesis during vertebrate development [33].
Heparin, a highly sulfated heparan sulfate with a
higher iduronate/glucuronate ratio and a higher percent-
age of sulfated domains than heparan sulfate [12], and
specific heparan sulfate/heparin preparations (hepari-
noids) are known to have strong anticoagulant and anti-
inflammatory activities [11, 24, 34–39]. This review aims
to summarize the current knowledge of the role of HSPGs
in glomerular inflammation.
INFLAMMATION
Tissue injury caused by infection or physical dam-
age evokes inflammatory reactions and events that are
necessary for regaining normal homeostasis. Central to
these events is the translocation of leukocytes, includ-
ing monocytes, neutrophils, and T lymphocytes, from
the vascular system through the endothelium and the
extracellular matrix (ECM) to the injured tissue [40].
This transendothelial migration occurs in a sequential
four-step process and involves the concerted action of
chemoattractants and adhesion promoting molecules,
like selectins and integrins (Fig. 2) (Table 2) [13, 40–
42]. In the first step, chemoattractants, cytokines, and
complement components, generated in the local inflam-
matory area, lead to activation of endothelium and
leukocytes. Up-regulation of local and systemic cy-
tokines, like tumor necrosis factor-a (TNF-a) and
interleukin-1b (IL-1b), induces expression of intercel-
lular and vascular adhesion molecules (ICAM and
VCAM), and selectins on the endothelium, by which the
leukocytes roll over the endothelial monolayer. Tether-
ing interactions, which involve the interaction of the L-
and P-selectins with cell surface–associated heparan sul-
fate [20, 25, 43], between leukocytes and endothelial cells
cause circulating cells to slow down and roll along the ves-
sel wall. In the second step, triggering factors, principally
cytokines, which may be bound to endothelial cell surface
heparan sulfate [22, 40, 42], activate leukocyte adhesion
molecules, the integrins, thereby promoting strong adhe-
sion that can stop the rolling leukocyte. The third step
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Fig. 2. Sequential steps in adhesion of leukocytes to endothelium. Upon tissue injury, for example podocyte injury, rolling and subsequent de-
acceleration of leukocytes is facilitated by reversible binding of L-and P-selectins expressed on respectively leukocytes and endothelium. Presented
chemokines are permitted easier access to the leukocyte, leading to activation of integrins and subsequent binding to their adhesion molecules on
the endothelium. Under the influence of additional chemokines, strongly adhering and flattened leukocytes will undergo diapedesis. Abbreviations
are: RBC, red blood cell; RANTES, regulated upon activation, normal T-cell expressed and secreted; MCP-1, monocyte chemoattractant protein-1;
TNF-a, tumor necrosis factor-a; IL-6, interleukin-6; iNOS, inducible nitric oxide synthase; TGF-b , transforming growth factor-b ; NO, nitric oxide;
O2−, superoxide; ONOO−, peroxynitrite anion; OH−, hydroxyl radicals; OCl−, hypochlorite anion [adapted with permission from Adams and
Shaw, 1994 [40] and from De Greef KE: Role of Inflammatory Cells in the Early Phase After Acute Renal Injury (Ph.D. thesis), University of
Antwerp, Belgium 2001].
Table 2. Adhesion molecules in leukocyte-endothelial interactions
Major families Individual members Cellular distribution Ligands on target cells
Selectins P-selectin Endothelial cells, PSGL-1, sLex, HSPGs/
platelets heparin, other
glycoconjugates
E-selectin Endothelial cells ESL-1, CLA, sLex, PSGL-1,
L-selectin, other
glycoconjugates
L-selectin Leukocytes CD34, GlyCAM-1,
MAdCAM-1, HSPGs/
heparin, CLA, sLex, E-selectin,
various fucosylated and
sulfated carbohydrates
Integrins aL b2 (LFA-1; Leukocytes ICAM-1, ICAM-2, ICAM-3
CD11a/CD18)
aM b2 (Mac-1; CR3; Granulocytes, monocytes ICAM-1, fibrinogen,
CD11b/CD18) HSPGs/heparin, iC3b
aX b2 (CR4; p150,95; Granulocytes, monocytes iC3b
CD11c/CD18)
a5 b1 (VLA-5; CD49/CD29) Monocytes, lymphocytes, VCAM-1, fibronectin
eosinophils
Immunoglobulin ICAM-1 (CD54) Endothelial, epithelial, LFA-1, Mac-1
superfamily mesangial, smooth muscle cells
ICAM-2 (CD102) Endothelial cells, LFA-1
lymphocytes, platelets
VCAM-1 (CD106) Endothelial, epithelial, VLA-4
mesangial, smooth muscle cells, monocytes
PECAM-1 (CD31) Endothelial cells, platelets, CD31
monocytes, granulocytes
Abbreviations are: PSGL-1, P-selectin glycoprotein ligand-1; sLex, sialyl-Lewisx; ESL-1, E-selectin ligand-1; CLA, cutaneous lymphocyte antigen; GlyCAM-1,
glycosylation-dependent cell adhesion molecule-1; MAdCAM-1, mucosal lymphoid adressin-1; LFA-1, lymphocyte associated antigen-1; Mac-1, macrophage-1 antigen;
VLA, very late antigen; ICAM, intercellular adhesion molecule; VCAM-1, vascular cell adhesion molecule-1; PECAM-1, platelet-endothelial cell adhesion molecule-1
[13, 40–42].
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in leukocyte recruitment depends on tighter adhesion,
via ICAM and VCAM on the endothelium. These ad-
hesion molecules bind to heterodimeric proteins of the
integrin family on the leukocytes, which are activated
by heparan sulfate–bound chemokines [19, 40, 42]. In
the fourth step, the leukocyte transmigrates or crosses
the endothelial monolayer (diapedesis). This step also
involves VCAM, ICAMs, and integrins, as well as a fur-
ther adhesive interaction involving an immunoglobulin-
related molecule called platelet-endothelial cell adhesion
molecule-1 (PECAM-1/CD31), which is expressed both
on the leukocyte and at the intercellular junctions of en-
dothelial cells. These interactions enable the phagocyte
to squeeze between the endothelial cells and to pene-
trate the basement membrane by the release of prote-
olytic enzymes. The leukocytes then migrate through the
tissues under the influence of chemokines [19, 40–42,
44]. Diapedesis and leukocyte migration in the injured
tissue are directly influenced by heparan sulfate–bound
chemokine gradients. Finally, leukocyte migration and
the combined action of heparan sulfate and heparan
sulfate–bound chemokines are influenced by the heparan
sulfate–degrading enzyme heparanase, which can be pro-
duced both by endothelial cells and leukocytes [26, 45–
47]. As will be discussed below in more detail, HSPGs
are involved in several steps of this inflammatory reac-
tion leading to transendothelial migration of leukocytes.
In the next paragraphs, we first will introduce the HSPGs
present in the ECM and at the cell surface of various cell
types.
GLOMERULAR PROTEOGLYCANS
The kidney contains a large number of functional units,
the so-called nephrons. Each nephron is composed of
a glomerulus, proximal tubule, loop of Henle, and dis-
tal tubule. A layer of parietal epithelial cells on a base-
ment membrane (called Bowman’s capsule) encapsulates
the glomerulus, which is a specialized tuft of capillaries
with the afferent and efferent arteriole at either end.
The wall of the glomerular capillary consists of a sin-
gle layer of fenestrated endothelial cells, attached to the
glomerular basement membrane (GBM), which is cov-
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Fig. 3. Molecular anatomy of the glomerular basement membrane (GBM)-associated heparan sulfate proteoglycans (HSPGs). Perlecan
is a HSPG of which domain I is the only unique region. This module contains an acidic region followed by three repeated Ser-Gly-Asp sequences,
which are the primary heparan sulfate attachment sites for perlecan. Domain II of perlecan is homologous to the class A, low-density lipoprotein
(LDL) receptor. Domain III contains modules with homology to the laminin epidermal growth factor (EGF)-like domain (LE) and the laminin
B domain (LamB). Domain IV contains a repeat of immunoglobulin (Ig) IgG modules, similar to neural cell adhesion molecule (NCAM),
and domain V is the C-terminus of perlecan, containing three laminin G domain like modules (LamG) spaced by two EGF-like modules. It
also contains an additional substitution site for an heparan sulfate chain. Agrin is a multimodular composition of a globular laminin-binding
domain, nine follistatin-like protease inhibitor domains, two laminin-like (EGF repeats, two serine/threonine (ST)-rich domains, one SEA (sperm
protein-enterokinase-agrin) module, four EGF repeats and three domains sharing homology with globular domains of laminin G. There are three
glycosaminoglycan (GAG) attachment sites located N-terminally to the SEA domain. Collagen XVIII is a nonfibrillar collagen. Its domains are
characterized by the spacing of collagenous and non-collagenous regions. The endostatin domain is present at the C-terminus. The bottom panel
provides the key to the protein modules and GAG attachment sites.
ered at the other side with visceral epithelial cells, also
called podocytes. The GBM is a dense network of inter-
acting ECM molecules, such as collagens, laminins, and
HSPGs. Formation of the meshwork of molecules is also
facilitated by multiple binding interactions of heparan
sulfate. The GBM plays a key role in glomerular filtra-
tion by providing mechanical support to the glomeru-
lar capillary wall and by regulating the access of plasma
molecules to the tubular system of the nephron. The
permeability through the glomerular capillary wall for a
given molecule is highly dependent on its size, shape, and
charge. The charge-selective permeability of the GBM
is largely determined by the electrostatic properties of
heparan sulfate within the GBM [3, 48]. The HSPGs per-
lecan, agrin, and collagen XVIII are ECM components
localized in the GBM [49–52]. In addition to the ECM,
HSPGs are also present at the cell surface of various cell
types, including endothelial cells and leukocytes. These
cell surface HSPGs include glypicans, syndecans, CD44,
and betaglycan [1, 13, 53, 54]. In contrast to the HSPGs
in the GBM, they are probably not so important for the
charge-dependent permeability of the GBM, but they
have other functions, also in the process of inflammation.
Syndecan and glypican expression is often associated with
morphological transitions or major changes in tissue or-
ganization [1, 55]. Syndecan-1, -3 and -4 and glypican-
1 are differently expressed by different endothelial cell
types [13]. Betaglycan is a type III transforming growth
factor-b (TGF-b) receptor and is present in the cortical
renal interstitium [53, 56] and on microvascular endothe-
lial cells [57]. CD44, a cell surface receptor for the GAG
hyaluronic acid (HA), is expressed by mesangial cells [58,
59], and different endothelial cell types [13].
GBM-associated HSPGs
The perlecan core protein contains five domains based
on amino acid homology with other known proteins
(Fig. 3) [60]. There are three GAG attachment se-
quences located in close proximity to each other in
domain I (unique for perlecan) at the N-terminal end
of the molecule. One additional substitution site for a
heparan sulfate chain has been localized to domain V
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[61] and there is one alternate splice site in domain
IV. Chondroitin sulfate or dermatan sulfate chains occa-
sionally replace heparan sulfate chains in perlecan [4].
Chondroitin sulfate consists of N-acetyl-galactosamine
and glucuronate disaccharides and it can be sulfated
at positions 4 and 6 of the N-acetyl-galactosamine unit
and at position 2 of the uronic acid residue [5]. Der-
matan sulfate, a form of chondroitin sulfate in which
the glucuronate has been epimerized to iduronate dur-
ing transport to the cell surface, contains 10% to 15%
of iduronate [62]. Perlecan expression correlates uni-
versally with tissue maturation and is always prominent
in the endothelial basement membranes of all vascu-
larized organs [4]. In the kidney, perlecan is present
in the GBM, Bowman’s capsule, and the tubular base-
ment membrane (TBM) [49, 63]. Perlecan is also local-
ized in the mesangial matrix, predominantly on the en-
dothelial side with a nonhomogenous distribution [49].
Immunofluorescence analysis shows that the expression
of perlecan is higher in the mesangium than in the
GBM [3]. Perlecan binds to the basement membrane
components, laminin, collagen IV, entactin/nidogen, and
fibulin [64, 65]. Perlecan has also been found to bind
the ECM component fibronectin via its heparan sulfate
chains [64, 66], but also via its core protein [66]. It also
binds to the podocyte cell surface–associated protein
a-dystroglycan by its conserved laminin G domains [67].
Recently, it has been shown that the C-terminal domain
of perlecan (endorepellin) interacts with the C-terminal
domain of collagen XVIII (endostatin), another GBM-
associated HSPG, thereby counteracting its angiogenic
effects [68]. Until recently, it was thought that perlecan
was important for the permeability of the GBM. How-
ever, a mouse with a targeted disruption of domain I
(containing the heparan sulfate attachment sites) of per-
lecan did not show renal abnormalities, nor proteinuria
but developed lens degeneration [69].
The protein sequence of agrin also shows homolo-
gies with other known proteins (Fig. 3) [70, 71]. Three
GAG attachment sites are located N-terminally to the
sperm protein-enterokinase-agrin (SEA) domain. There
are three alternative splice sites, x, y, and z, one near
the N-terminus and two at the C-terminus [72, 73], but
there are also short NH2-terminal (SN) and long NH2-
terminal (LN) isoforms [74]. Agrin is the most abundantly
expressed HSPG in the GBM [50], while expression is less
in the TBM, Bowman’s capsule, and vascular walls [70].
There are differences in the distribution of SN and LN
isoforms and N-terminal and C-terminal agrin [50]. SN-
agrin is selectively expressed in the nervous system, while
LN-agrin is expressed in both neural and non-neural tis-
sues, including the GBM [74]. N-terminal agrin is present
in all renal basement membranes, including the TBM,
while C-terminal agrin is almost exclusively expressed
in the GBM, which indicates the existence of several
isoforms of agrin in the kidney (i.e., a “large” agrin con-
taining both the C- and N-terminus and a “shorter” vari-
ant missing C-terminal regions). The existence of these
isoforms might be due to alternative splicing and/or post-
translational processing. HSPGs influence the glomerular
permeability by their negatively charged heparan sul-
fate side chains [3, 48]. Injection of a monoclonal an-
tibody against GBM-associated heparan sulfate induces
instantly a massive albuminuria [31]. Agrin acts as a ma-
jor structural component of the GBM that interacts with
components of the matrix as well as with components
at the surfaces of podocytes. The heparan sulfate side
chains on the N-terminal half of agrin bind to the hep-
arin binding site on the neural cell adhesion molecule
(NCAM) and to heparin-binding proteins in the base-
ment membrane [75], like laminin, fibronectin, and the
membrane-associated glycoprotein a-dystroglycan ex-
posed by podocytes [76, 77], which facilitates the forma-
tion of the GBM.
In addition to agrin and perlecan, collagen XVIII is
also an ECM-associated HSPG expressed in the kidney
[52]. It is more prominent in the mesangium than in the
GBM [3]. Collagen XVIII has three GAG attachment
sequences for heparan sulfate (Fig. 3) [78]. Alternative
splicing at the N-terminus produces long and short forms
of the molecule. The alternate spliced variants are dif-
ferently expressed in different tissues. The short variant
is predominantly present in the fetal and adult kidney
[79]. Endostatin is a carboxy-terminal proteolytic cleav-
age product of collagen XVIII that significantly inhibits
endothelial cell proliferation and migration and also in-
hibits angiogenesis [80, 81]. Recently, it has been shown
that endostatin co-localizes with perlecan in basement
membranes [82]. It has been shown that the inhibitory
effect of endostatin on vascular growth factor-induced en-
dothelial migration is blocked by a 10/12 mer endostatin-
binding sequence of heparan sulfate [83].
Cell surface HSPGs
Syndecans are type I transmembrane HSPGs, with
an extracellular domain that contains several consen-
sus sequences for GAG attachment, a single hydropho-
bic transmembrane domain, and a short C-terminal
cytoplasmic domain (Fig. 4) [1]. This class of transmem-
brane molecules is a family of four members: syndecan-
1 (syndecan), syndecan-2 (fibroglycan), syndecan-3
(N-syndecan), and syndecan-4 (ryudocan, amphiglycan)
[1, 9, 84]. Whereas the majority of GAG chains attached
to syndecan core proteins are of the heparan sulfate
type (Fig. 4), syndecan-1 [85] and syndecan-4 [86] may
also contain chondroitin sulfate. Syndecan-1 and -3, and
syndecan-2 and -4 can be considered to form subfamilies
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Fig. 4. The four families of cell surface heparan sulfate proteoglycan (HSPG) core proteins, which contain heparan sulfate (HS) and/or chondroitin
sulfate (CS) side chains. Six isoforms of glypican (in this figure only two isoforms of glypican are represented), four isoforms of syndecan, and
numerous isoforms of CD44, (with the standard form CD44H) exist.
based on sequence similarities, GAG attachment sites,
and core protein size. The cytoplasmic domains are short,
highly conserved, and may interact with cytoskeletal el-
ements and kinases, which has implications for signal
transduction events [87, 88]. The length of the extracel-
lular domain varies markedly among the different family
members [1, 84]. Syndecan-1, -2, and -4 are expressed
by vascular endothelial cells, predominantly at the ba-
solateral surfaces [84, 89]. Only syndecan-1 and -4 are
expressed in the kidney. Syndecan-1 is present at the
basolateral surface of renal epithelial cells [90, 91] and
syndecan-4 is predominantly present on endothelial cells
[92]. Syndecan-4 is the only syndecan consistently found
in focal adhesions, which are specialized regions of the
plasma membrane that mediate tight adhesion between
the cell and the underlying ECM [87, 88, 93]. It is a reg-
ulator of focal adhesion and stress fiber formation, and
influences both cell morphology and migration [94]. Syn-
decan expression is often associated with morphologic
transitions or major changes in tissue organization, such
as in development [1, 84, 92]. Both cell surface expres-
sion and shedding of syndecan-1 and -4 are increased
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in response to injury and play a role in inflammation
[1, 10].
The glypicans are a family of HSPGs that are linked
to the outer surface of the plasma membrane through
a covalent glycosyl-phosphatidylinositol (GPI) anchor
(Fig. 4) [9]. There are six known members of the glypican
family: glypican-1 (glypican), glypican-2 (cerebroglycan),
glypican-3 (OCI-5), glypican-4 (K-glypican), glypican-5,
and glypican–6. All share a modular structure with a large
extracellular domain, including a cysteine-rich globular
region, and carry exclusively heparan sulfate chains. The
core protein of all glypicans is roughly of similar size and
contains Ser-Gly repeats in their C-terminal parts, which
are the attachment sites for heparan sulfate chains [55,
84, 95]. All glypicans are highly expressed during embry-
onic development. Expression levels have been shown
to change in a stage- and tissue-specific manner, suggest-
ing that glypicans are involved in morphogenesis [55, 96].
Glypican-1 [55], -3 [97], -4 [98], and -5 [96] are expressed
in the (developing) kidney. Glypican-5 mRNA is ex-
pressed by pretubular aggregates and early tubular struc-
tures, but is down-regulated before complete glomerular
structures are formed [96]. Glypican-1 is expressed by
early epithelial aggregates, but persists in their glomeru-
lar derivatives. It is also shown that this glypican is present
on vascular endothelial cells [99]. Glypican-3 directly con-
trols collecting duct cell responses [97] and glypican-4
is associated with mature tubular, but not glomerular,
derivatives [98]. Glypican-3 also plays an important role
during renal development, since this HSPG is mutated in
a mouse model of Simpson-Golabi-Behmel (overgrowth)
syndrome that includes renal abnormalities [100]. In ad-
dition to their role in development, another function of
glypicans is to serve as low-affinity receptors for endo-
statin in renal tubular and arterial endothelial cells [95].
Although endothelial cells express glypican-1, a role of
glypicans in inflammation is not as clear as for the synde-
cans [2, 54].
Betaglycan has been shown to contain both heparan
sulfate and chondroitin sulfate chains (Fig. 4) and is
present in the cortical renal interstitium [53, 56] and on
microvascular endothelial cells [57]. Betaglycan is a type
III TGF-b receptor that binds various forms of TGF-b
with high affinity and specificity [53, 56]. The core pro-
tein binds TGF-b and associates with type II receptor in
a ligand-dependent manner, thereby modulating the ef-
fects of TGF-b [101]. The GAG chains of betaglycan are
not necessary for the expression of betaglycan at the cell
surface, the binding of TGF-b to the betaglycan core pro-
tein, and the inhibitory effect of TGF-b [102]. A naturally
occurring soluble form of betaglycan is found in serum
and in the ECM [101]. Betaglycan is involved in glomeru-
lar inflammation, since its mRNA expression is increased
in various types of glomerulonephritis [56]. The expres-
sion of TGF-b is also up-regulated in decorin-deficient
mice with unilateral ureteral kidney obstruction. Decorin
is a small dermatan sulfate proteoglycan and a member of
the family of small leucine-rich proteoglycans (SLRPs).
Decorin appears to form complexes with TGF-b and ex-
erts beneficial effects on tubulointerstitial fibrosis [103].
CD44 is a so-called “part-time” proteoglycan, which
means that it can exist in a proteoglycan and nonpro-
teoglycan form. The GAG chains can be either chon-
droitin sulfate or heparan sulfate. Like syndecans it has
a short highly conserved intracellular domain and a large
extracellular domain (Fig. 4) [104]. CD44 is a cell surface
glycoprotein that is encoded by one single gene, but ex-
pressed in numerous isoforms. The highly tissue-specific
expression is due to differential splicing of up to twelve
alternative exons into a single site within the extracellular
domain. The standard form of CD44 (CD44H) contains
the products of exons 1–5 and 16–17. Splicing events may
result in isoforms that lack transmembrane and cytoplas-
mic domains, thus yielding secreted, soluble CD44 [105].
However, soluble CD44 can also arise via shedding from
the cell surface, apparently as a result of proteolytic cleav-
age [106]. CD44 is a cell surface receptor for HA and is
involved in the homing of lymphocytes [107]. It is syn-
thesized by synovial epithelial cells, synovial fibroblasts,
glial cells, Kupffer cells [107], mesangial cells [58, 59],
and different endothelial cells [13]. In endothelial cells
[108] and macrophages [109], interaction of low molecu-
lar weight HA with CD44 leads to the activation of the
immediate early-response genes involved in proliferation
and inflammation. HA, a constituent of the ECM, is a
nonsulfated, linear GAG consisting of repeating units of
N-acetyl-glucosamine and glucuronate molecules. HA is
synthesized by specific HA synthases in all mammalian
cells and it is extruded into the extracellular space by
these plasma membrane enzymes [110]. HA also plays
an important role in inflammation, since the expression
of HA on endothelial cells is induced by proinflammatory
cytokines [111]. HA fragments can induce chemokine ex-
pression in alveolar macrophages, which can be inhibited
by CD44 [109].
In addition to the expression at the surface of endothe-
lial cells (syndecan-1, syndecan-2, syndecan-4, glypican-
1, CD44, and betaglycan), mesangial cells (CD44), and
visceral/tubular epithelial cells (betaglycan, syndecan-1,
and glypican-1), cell surface HSPGs are also expressed on
leukocytes [112–117]. HSPGs, such as CD44, on leuko-
cytes help to regulate leukocyte trafficking in tissues,
participating in the rolling interactions with HA on en-
dothelial cells. CD44 and syndecan-2 are specifically
up-regulated on macrophages, following in vitro differ-
entiation and activation with IL-1 and lipopolysaccharide
[112, 113]. Syndecan-1 and -4 are expressed on leukocytes,
including B cells [114] and macrophage-like cells [115],
while syndecan-4 is also expressed on neutrophils [116],
and peripheral blood monocytes [117].
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ROLE OF HSPGS IN GLOMERULAR
INFLAMMATION
Chemotaxis and HSPGs
Chemokines that are produced by endothelial cells or
platelets, which are often the initial cells responding to
injury, become often localized on the vascular endothe-
lium via interaction with GAGs. Chemokines are ba-
sic proteins, which bind to negatively charged heparin
and heparan sulfate [22]. The capture of chemokines
by HSPGs in the ECM and on the surface of endothe-
lial cells creates a local concentration gradient at the
point of chemokine production. HSPGs on leukocytes
also sequester chemokines and trigger integrin-mediated
T-cell adhesion. The chemokines are a family of small
chemoattractant proteins that are capable of activat-
ing and promoting vectorial migration of a variety of
leukocytes [118]. Chemokines can be grouped into four
subfamilies dependent on the position of conserved
cysteine residues, designated C, CC, CXC, and CX3C.
Lymphotactin and fractalkine are the prototypes of
respectively the C and CX3C subclass [119, 120]. Lympho-
tactin has chemotactic activity for lymphocytes, but not
for monocytes or neutrophils [120]. Soluble fractalkine
is chemoattractive for T cells and monocytes, while cell
surface-bound fractalkine, which is induced on acti-
vated endothelial cells, promotes strong adhesion of
those leukocytes [119]. The CXC subclass mediates
acute inflammatory reactions mainly via neutrophil at-
traction and activation, and includes IL-8, SDF-1a,
PF-4, IP-10, and GRO-a, -b , and -c, which all bind
to heparin/heparan sulfate. The CC subclass is impli-
cated in chronic inflammation through the attraction
of lymphocytes, eosinophils, basophils, dendritic cells,
and macrophages, and includes RANTES, eotaxin, SLC,
TARC, macrophage-derived chemokine (MDC), MIP-
1 through 3-a, -b , -c, and MCP-1 through-4, which
also bind to heparin/heparan sulfate. These chemokines
are expressed by many cell types, including leukocytes
and endothelial cells, and they interact with a family
of seven transmembrane receptors, the CC- and CXC-
chemokine receptors (CCRs and CXCRs), that are pre-
dominantly expressed on leukocytes [22, 40, 118], but
also by podocytes [121]. The GAGs that are present on
the cells help to increase locally the concentration of
chemokines on the cell surface by inducing chemokine
oligomerization and facilitating presentation to their re-
spective receptors [122]. However, it was shown that
GAG expression is not necessary for the biologic activity
of the chemokines MIP-1a, RANTES, or MIP-1b , but
cell surface–associated GAGs do enhance the activity of
low concentrations of these chemokines by sequestration
at the cell surface [15, 16]. Conversely, chemokines can
also bind soluble GAGs and the complexes formed are
unable to bind to the receptor, resulting in a block of the
biologic activity. The chemokines IL-8, MCP-1, MIP-1a,
and RANTES bind to endothelial GAGs, with a higher
preference for O-sulfation than N-sulfation [123]. SDF-
1a interacts selectively and with high affinity with hep-
aran sulfate in vitro. SDF-1a binds to highly sulfated,
heparin-like, sequences within heparan sulfate through
direct interaction via clusters of basic, positively charged
residues on SDF-1a [17, 124]. It can be concluded there-
fore that the interaction between chemokines and GAGs
can have different, sometimes opposite, functions.
In many proliferative forms of glomerulonephritis,
there is a massive influx of monocytes, neutrophils, and T
cells into the glomerulus [125] recruited by both mesan-
gial and endothelial cells [126]. The chemokines MCP-
1, MIP-1a, MIP-1b , RANTES, and IL-8 are thought to
be involved in this leukocyte infiltration [127]. Mesangial
cells secrete the CC chemokines MCP-1 and RANTES
[128, 129], the CXC chemokines IL-8 (CXCL8), and
GRO (CXCL1) [130, 131], while glomerular endothe-
lial cells exhibit inducible expression of the chemokines
RANTES and MCP-1 [132, 133]. Moreover, immunoflu-
orescence staining in nephritic, but not normal, kidneys
has demonstrated that the CX3C chemokine fractalkine
is expressed in a non-linear pattern typical of glomeru-
lar endothelium [18, 134]. In a study about the role
of chemokines and their receptors produced by mesan-
gial or glomerular endothelial cells in the recruitment of
monocytes [135], it has been shown that after TNF-a stim-
ulation of mesangial cells, GRO-a, and IL-8 are immobi-
lized on the mesangial cell surface via binding to HSPGs,
whereas MCP-1 is secreted. Endothelial cell activation
with TNF-a results in surface immobilization of GRO-a,
secretion of MCP-1, and up-regulation of fractalkine at
the cell surface [135, 136]. Soluble MCP-1 is required for
the intraglomerular influx of monocytes [135], while the
chemokines GRO-a and IL-8, via their receptor CXCR2,
are crucial for firm arrest of monocytes and neutrophils
[136]. These results indicate that an ordered sequence of
events, enacted by chemokines and their receptors, drives
glomerular monocyte infiltration. Recently, it has been
shown that in the rat the heparan sulfate chains of col-
lagen XVIII interact with MCP-1 and after presentation
to a monocytic cell line induce a4b1 integrin activation in
vitro. This may indicate that collagen XVIII binds locally
produced MCP-1 and presents it to infiltrating monocytes
in the inflamed glomerulus [137].
Leukocyte rolling and HSPGs
Heparan sulfate interacts with L- and P-selectins and
modulates leukocyte rolling [20, 43]. Moreover, hepari-
nase treatment, which leads to heparan sulfate degrada-
tion, inhibits significantly the monocyte attachment to
TNF-a-stimulated aortic endothelium under flow con-
ditions by inhibiting L-selectin binding to these cells
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[43]. The selectins of the adhesion cascade, L-, E-, and
P-selectin, are a family of adhesion molecules, which
mediate the initial step, “rolling,” leading to the re-
cruitment of leukocytes to sites of inflammation (Fig. 2)
(Table 1). L-selectin is expressed at the surface of leuko-
cytes, E-selectin on endothelial cells, and P-selectin on
platelets and endothelial cells [42]. All selectins interact
with the tetrasaccharide sialyl-Lewisx, consisting of sia-
lylated, fucosylated galactosamine structures, and with
heparin-like structures [24]. An in vitro study showed that
HSPGs from cultured human umbilical vein endothelial
cells (HUVECs) and aortic endothelial cells that bind to
L-selectin are enriched in free amino groups in the glu-
cosamine residues on their heparan sulfate chains [25].
Subsequently, it was shown that these heparan sulfate
chains could also bind to P-selectin, but not to E-selectin
[20]. E-selectin expressed at the surface of endothelial
cells did not bind to heparin [24], while the binding of sol-
uble E-selectin to capillary endothelial cells was blocked
by heparin, chondroitin sulfate, and the HSPG syndecan-
1, but not by sialyl-Lewisx-containing oligosaccharides
[138], indicating that heparan sulfate and/or chondroitin
sulfate proteoglycans on the endothelial cell surface may
be ligands for soluble E-selectin. The properties of hep-
arin to inhibit the binding of E-selectin to capillary en-
dothelial cells are critically dependent on 6-O-sulfated
glucosamine residues, while N-sulfation seems not im-
portant [139]. The anti-inflammatory activity of heparin
in vivo is largely determined by its interactions with P- and
L-selectin. Thus endothelium-derived heparan sulfate,
but also leukocyte-derived heparan sulfate, may have
a role in modulating the biologic function of selectins.
Moreover, it has been shown that syndecan-1 affects the
slow rolling of leukocytes on the surface of activated en-
dothelium, since in the absence of syndecan-1 the num-
ber of rolling leukocytes and their average velocity were
reduced [140]. Thus, syndecan-1 acts as a negative mod-
ulator of leukocyte-endothelial interactions. The lack of
syndecan-1 could lead to a dys-regulation of chemokine
action, or to an exposure of heparin binding sites on
molecules involved in the leukocyte-endothelium adhe-
sion process [10].
Ligands for L-selectin are expressed not only on high
endothelial venules (HEV) in the lymph nodes, but also
in the distal tubuli and capillary blood vessels of the
kidney [141]. The L-selectin-reactive molecules on HEV
are sialyl Lewisx-like carbohydrates, while the L-selectin-
reactive molecules in the kidney are chondroitin sulfate
proteoglycans (CSPGs) and HSPGs. L-selectin binds to
the HSPG via its lectin domain in a Ca2+-dependent man-
ner and requires heparan sulfate side chains, while sialic
acid is not involved [142]. The reactive HSPGs are nei-
ther agrin nor perlecan, the major basement membrane
HSPGs in the kidney. A recent study [137] showed that
these L-selectin-binding HSPG in the kidney, with core
proteins sizes of 160 and 180 kD, were both collagen
XVIII. Collagen XVIII in the basement membranes of
the renal tubules of the outer medulla binds L-selectin,
whereas collagen XVIII in the glomeruli and tubules in
the renal cortex does not bind L-selectin [137]. This im-
plies that only a subset of collagen XVIII species present
in the kidney is reactive with L-selectin. It has been sug-
gested that besides free amino groups also N- and O-
sulfation of heparan sulfate chains are required for the
interaction with L-selectin [25, 137].
Leukocyte adhesion and HSPGs
In the previous paragraph, we discussed the involve-
ment of HSPGs in the selectin-dependent rolling and
weak adhesion of leukocytes to endothelial cells. For
strong adhesion and emigration of leukocytes integrins
are important. Integrins mainly act as matrix receptors,
and tie the ECM to the cytoskeleton. In blood cells they,
however, act as cell-cell adhesion molecules. These inte-
grins are heterodimers consisting of an a and a b chain.
Integrins have been arranged in subfamilies according
to the b subunits and each b subunit can be associated
with eight different a subunits. However, individual a
subunits may also be associated with several different b
subunits [143]. Integrin activation depends on chemokine
action, which is modulated by heparan sulfate. Also the
expression of integrin ligands, like ICAM-1, on target
cells is induced by heparan sulfate [144]. Heparan sul-
fate is an adhesive ligand for Mac-1 (CD11b/CD18), a b2
integrin expressed on leukocytes (Fig. 2) (Table 1). It has
been shown that complete desulfation of heparin signifi-
cantly reduced its binding to Mac-1, whereas N-sulfation
of N-acetyl-glucosamine restored adhesion. Since forms
of heparin that lack N-sulfation are still capable of bind-
ing to Mac-1, secondary O-sulfated moieties are also
sufficient for heparin to bind efficiently to Mac-1. Con-
tinuous flow experiments with heparins and E-selectin as
cosubstrates showed that neutrophils tether to E-selectin
and form strong adhesions through a Mac-1-heparin in-
teraction [19]. It has been shown that syndecan-1 acts as
a negative modulator in the adhesion process, since ab-
sence of syndecan-1 increases the b2 integrin-dependent
adhesion process of neutrophils, monocytes, and lympho-
cytes to the vessel wall [140]. Recently, it has been shown
that the enzyme heparanase that cleaves heparan sulfate,
mediates cell adhesion to ECM independent of its en-
zyme activity [46].
The accumulation of the GAG matrix molecule HA in
the cortical renal interstitium is linked to classic proin-
flammatory events in the kidney [145]. Accumulation of
HA, its breakdown into low-molecular-weight products
by specific hyaluronidases or oxygen-free radicals, and
the subsequent stimulation of chemokines, cytokines, and
adhesion molecules leads to a coordinated inflammatory
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response that could occur in many renal injury processes.
The expression of CD44, the HA receptor, is markedly
enhanced in inflammatory renal diseases (lupus nephri-
tis and anti-GBM glomerulonephritis), particularly at the
cell surface of tubular epithelial cells and in glomerular
crescents [145, 146]. HA fragments of a defined size up-
regulate the adhesion molecules ICAM-1 and VCAM-1,
which suggests a possible link between matrix degrada-
tion and leukocyte adhesion [147].
Leukocyte transmigration and HSPGs
Heparan sulfate not only affects leukocyte adhesion
to a stimulated endothelium, it also influences leukocyte
chemotaxis and transmigration [118]. Once the leuko-
cytes are firmly attached to the endothelium they are
able to crawl out of the blood vessel between adja-
cent endothelial cells. Activated and adherent leukocytes,
including polymorphonuclear cells (PMNs), release re-
active oxygen species (ROS), proteases, elastases, and
additional enzymes that damage the injured tissue di-
rectly, thereby enhancing inflammatory cell infiltration
and increasing vasoconstriction. These substances, to-
gether with the inflammatory mediators leukotriene-B4
and platelet-activating factor (PAF), increase vascular
permeability and up-regulate adhesion molecule expres-
sion on endothelial cells, thereby promoting further in-
flammation. It has been reported that PMNs as well as
cell-free neutrophil supernatants lead to a rapid and dra-
matic loss of proteoglycan from endothelial cells, which
is mediated by neutrophil-derived serine proteases [148].
Elastase and heparanase can be released during inflam-
mation by activated leukocytes and endothelial cells
[26, 45, 47, 148]. Elastase enhances additional inflam-
matory cell infiltration and can also enhance the effect
of heparanase. Heparanase action on intact ECM or
derivatives of heparin generates a trisulfated disaccha-
ride that inhibits secretion of active TNF-a by activated
T cells and macrophages, respectively. The inhibitory ef-
fects of the trisulfated disaccharide are lost if the sul-
fate groups are removed [149]. Inhibitors of neutrophil
elastase appear to be the most effective inhibitors of
proteoglycan release from endothelial cells. In addition,
GBM-associated HSPG is susceptible to proteolytic
cleavage by elastase. Intrarenal perfusion of elastase
leads to a dose-dependent loss of heparan sulfate in the
GBM, while HSPG core expression was only slightly re-
duced. The heparan sulfate loss is due to cleavage at
the serine residue, at the attachment site of the hep-
aran sulfate side chain [150]. Heparanase (HPA1 or
HPSE1) is a heparan sulfate–degrading enzyme that
plays an important role in inflammation. Heparanase
is a b-endoglucuronidase that degrades heparan sulfate
chains at specific sites and specifically hydrolyzes the b1
→ 4 bond between uronic acid and glucosamine residues
[151]. Heparanases can remove ligand-binding sites from
HSPGs either by cleavage of the heparan sulfate chain
from the core protein, or by cleavage of ligand binding
motifs in heparan sulfate [45]. Several blood-borne cells,
including macrophages, neutrophils, activated CD4+ T
cells, mast cells, monocytes, and platelets, but also en-
dothelial cells, exhibit heparanase activity [47, 152]. The
degradation of heparan sulfate moieties during inflamma-
tion by heparanase may facilitate passage of leukocytes
into tissues by altering the permeability of the ECM. In
addition to disrupting the ECM for immune cell passage,
the resultant products of heparanase-degraded substrates
(heparan sulfate–derived oligosaccharides) or the release
of heparan sulfate–bound inflammatory mediators may
actually potentiate other pro- or anti-inflammatory pro-
cesses [47].
Heparin-binding protein is an inactive protease ho-
mologue that is produced by activated neutrophils and
endothelial cells upon their interaction. Heparin-binding
protein is able to bind to a wide range of cell surface
HSPGs and may be endocytosed. Heparin-binding pro-
tein has an antiapoptotic effect on endothelial cells and
facilitates leukocyte influx in the injured tissue [21, 153,
154].
In certain proliferative forms of glomerulonephritis,
ROS can be released locally by infiltrating leukocytes,
which results in damage of the GBM and concomitant
proteinuria. Overproduction of ROS has also been found
in glomerular diseases in which the podocyte is the pri-
mary target of injury. The release of ROS leads to protein-
uria by affecting glomerular endothelial and epithelial
cells and disturbing normal glomerular permselectivity
[155, 156], most likely by degradation of GBM-associated
heparan sulfate [3, 28, 157]. The susceptibility of differ-
ent GAGs to depolymerization by ROS dependents on
the degree of sulfation; low- or nonsulfated GAGs are
more sensitive to depolymerization than high-sulfated
GAGs [157–159]. Although changes in heparan sulfate
during inflammation (and other pathologic processes in
the kidney) may be very dynamically, pinpointing to
specific changes of heparan sulfate may give clues for
the development of therapeutic heparin or heparan sul-
fate preparations, which we will address in the next two
paragraphs.
HSPG-RELATED ALTERATIONS IN
GLOMERULAR INFLAMMATION
As we have outlined previously, there are several mech-
anisms that can induce heparan sulfate alterations in
proteinuric diseases [3]. These mechanisms include (1)
masking of heparan sulfate by nucleosome containing
immune complexes; (2) depolymerization of heparan
sulfate by ROS; (3) proteolytic cleavage by elastase;
(4) hyperglycemia-induced heparan sulfate undersulfa-
tion and reduction of heparan sulfate production; and
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(5) proteolytic cleavage by complement factors. Some of
these mechanisms are related to inflammation. The evi-
dence for this will be discussed briefly.
Systemic lupus erythematosus (SLE) is an autoim-
mune disease characterized by a broad spectrum of
clinical manifestations, very often including renal in-
volvement. SLE-associated glomerulonephritis is associ-
ated with granular deposits of immunoglobulins (Ig) and
complement factors along the glomerular capillary wall
and in the mesangium. One study [160] showed that both
the extent of Ig deposits in the capillary loops and the
albuminuria were correlated with a decreased staining of
GBM-heparan sulfate, while the staining for the HSPG
core protein was not altered. The negative correlation be-
tween GBM-heparan sulfate and Ig deposits and between
GBM-heparan sulfate and albuminuria suggests that the
neutralization of heparan sulfate–related anionic sites in
lupus nephritis is caused by deposition of immune com-
plexes in the capillary loops thereby blocking the negative
charge of heparan sulfate. Instrumental for this complex
formation is the binding of nucleosomes to heparan sul-
fate. This binding is due to the binding of the positively
charged histones within the nucleosome to heparan sul-
fate. Heparin and noncoagulant heparin derivatives are
able to bind to these nephritogenic complexes by cover-
ing these positive charges in histones [36]. This binding
of heparin and heparin derivatives to the nucleosome-
autoantibody complexes prevents the subsequent de-
position of these nephritogenic immune complexes in
the GBM and reduces the glomerular inflammation and
albuminuria.
As outlined before, elastase and heparanase can be
produced by different inflammatory cells. In various pro-
liferative forms of glomerulonephritis a segmental re-
duction was observed for heparan sulfate staining in the
glomerulus [32]. It remains to be determined whether this
reduction in heparan sulfate staining is due to enzymatic
cleavage and/or ROS production exerted by the infiltrat-
ing glomerular cells.
An in vitro study with bovine glomerular endothe-
lial cells [161] showed that IL-1b , a proinflammatory cy-
tokine that activates endothelial cells and up-regulates
ICAM, MCP-1 [162, 163], and neutral GAG HA in mi-
crovascular endothelium [111], induces an increased syn-
thesis of sulfated GAGs by glomerular endothelial cells.
This effect may be a part of the cell defense to maintain
the permselective properties of the glomerular barrier.
Glomerular endothelial cells are capable of producing
heparan sulfate, chondroitin sulfate, and dermatan sul-
fate [164].
The differential expression of syndecans in response
to inflammatory stimuli was a first sign of their di-
rect involvement in these processes. The expression of
syndecan-1 can be induced on the surface of endothelial
cells in the context of inflammation [165], suggesting a
role for syndecan-1 in the interaction of leukocytes with
endothelial cells. Lack of syndecan-1 promotes the in-
crease in vascular permeability and leukocyte extravasa-
tion under inflammatory conditions [10, 140]. Also the
expression of syndecan-4 can be induced on endothelial
cells (and other inflammatory cells) in response to inflam-
matory stimuli [10, 166].
Since it can be envisaged that structural alterations in
HSPGs are be associated with renal inflammatory pro-
cesses, further study is warranted to unravel structural
and topologic alterations of HSPGs in glomerular inflam-
mation and to evaluate heparan sulfate domains as mark-
ers for progressive loss of renal function. These analyses
could provide clues for the therapeutic use of heparan
sulfate and/or heparin.
Overall, at this moment there is not much literature
on specific changes in heparan sulfate structure(s) in
relation to inflammation, especially glomerulonephritis.
Currently, we are analyzing (experimental) glomeru-
lonephritis models with single chain antibodies that are
specific for structural epitopes within heparan sulfate [14,
167–172].
HEPARAN SULFATE INTERVENTION
THERAPIES IN INFLAMMATION
It is plausible that heparan sulfate or heparin deriva-
tives affect inflammatory cell behavior and may have
promising therapeutic, anti-inflammatory properties [11].
As outlined, HSPGs are involved in several ways in the
activation of leukocytes and endothelial cells, the rolling,
the firm adhesion, and diapedesis of leukocytes through
the endothelium and subsequent migration into the tis-
sue, one can think of many potential targets for thera-
peutic heparin/heparinoid fractions (glycomimetics). In
several (inflammatory) diseases, like rheumatoid arthri-
tis and diabetic nephropathy, heparin/heparinoids are al-
ready clinically applied [173–175]. Indeed, it has been
shown that therapeutic intervention with heparinoids
prevents leukocyte adhesion/influx and disease manifes-
tation in inflamed tissue [43, 176]. However, the main
application of heparin/heparinoids still is its use as an-
ticoagulant. It can be more safely used as an anti-
inflammatory drug, if the anticoagulant properties are
abrogated, leaving the anti-inflammatory properties un-
changed. Partial chemical desulfation of heparin showed
that the anti-inflammatory effects of heparin are inde-
pendent of anticoagulant activity [11, 37, 177]. Heparin
blocks P- and L-selectin-initiated cell adhesion wherein
the sulfate groups at C6 on the glucosamine residues play
a critical role. Some nonanticoagulant forms of heparin
have the same effect and such analogues may be use-
ful as therapeutically effective inhibitors of inflamma-
tion [139]. In SLE, heparin and noncoagulant heparin
derivatives are equally effective in inhibiting the binding
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of nucleosome complexed antibodies to heparan sulfate
in the GBM. These drugs prevented the development of
glomerular lesions in MRL/lpr mice [36]. In an intrav-
ital microscopy study, administration of low-molecular-
weight heparin markedly reduced TNF-a-induced
leukocyte rolling, adhesion, and tissue infiltration [38].
When heparin was given after TNF-a, only leukocyte
rolling was reduced and not the firm adhesion of leuko-
cytes. However, heparin inhibits binding of soluble lig-
ands, like fibrinogen, factor X, and iC3b to Mac-1 [19].
Heparin also inhibits heparanase activity of neutrophils,
lymphocytes, endothelial cells and platelets as well as
ECM degradation [26]. Enoxaparin, a low-molecular-
weight heparin, protects cultured valvular endothelial
cells from activation and monocyte adhesion by inhibit-
ing the expression of the cell adhesion molecules ICAM-1
and E-selectin [39]. Another study with low-molecular-
weight heparin [35] showed that N-desulfated heparin
inhibits leukocyte adhesion and transmigration and has
the lowest anticoagulant activity among low molecu-
lar weight heparins and chemically modified heparin
derivatives.
Flow perfusion adhesion experiments with bone mar-
row endothelium and hematopoietic progenitor cells
showed that heparins inhibit both rolling and firm ad-
hesion, whereas heparan sulfate-GAGs inhibit firm ad-
hesion [178]. The same authors [179] showed that soluble
heparan sulfate but not heparin enhanced SDF-1 induced
migration. In vivo experiments with infused sulfated sac-
charides showed inhibition of the rolling of leukocytes
[34]. A rat model similar to human chronic progressive
glomerulonephritis has been used to study the therapeu-
tic effect of a sulfated neutral GAG, sulfated hyaluronic
acid (SHA) [180]. Proteinuria and leukocyte infiltration
into the glomeruli were inhibited by the administra-
tion of SHA in both the acute and the chronic phase.
SHA ameliorated rat proliferative glomerulonephritis by
inhibiting P-selectin-dependent leukocyte infiltration in
glomeruli.
As mentioned, the evaluation of heparan sulfate do-
mains as markers for progressive loss of renal function
and as potential therapeutics is important in glomeru-
lonephritides. If it becomes possible to define groups and
monosaccharide sequences of heparan sulfate that are
relevant in the inflammation process, specific heparan sul-
fate analogues may be developed to stop or influence this
inflammatory process.
CONCLUSION
There is convincing evidence that HSPGs not only play
an important role in the permeability of the GBM, but
also are important in glomerular inflammation. HSPGs
capture chemokines in the ECM and on the surface
of glomerular endothelial cells to establish a local con-
centration gradient by inducing chemokine oligomer-
ization and facilitating their presentation to receptors.
Chemokines can also bind soluble GAGs, which results
in a blockade of their biologic activity. HSPGs are not
only involved in the mobilization and attraction of in-
flammatory cells, they also promote adhesion, diapedesis,
and migration. Heparan sulfate chains bind both L-
selectin and the b2 integrin Mac-1. Several leukocytes,
like macrophages, neutrophils, activated CD4+ T cells,
mast cells, and endothelial cells, exhibit heparanase ac-
tivity, which degrades heparan sulfate, thereby facilitat-
ing passage of lymphocytes into tissues and potentiating
other pro- or anti-inflammatory processes. Several im-
portant studies described in this review showed that hep-
aran sulfate or heparin derivatives affect the behavior of
inflammatory cells and have promising therapeutic and
anti-inflammatory properties by preventing leukocyte ad-
hesion/influx and glomerular damage.
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